Drug Trial Radar · NCT04677842
European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol
Last checked: Nov 19, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10,000
Actual
Start
Jan 1, 2013
Primary completion
Nov 11, 2020
Study completion Jan 1, 2025
Sponsor
- Lead sponsor
- PENTA FoundationResearch network
- Sponsor type
- Research network
- Collaborators
- University College, London; Centre Hospitalier Universitaire Saint Pierre; German Pediatric and Adolescent HIV Cohort (GEPIC), GERMANY; Greece Cohort, GREECE; Register for HIV infection in children, ITALY; ATHENA ,THE NETHERLANDS; Polish Paediatric Cohort, POLAND; HSM/CHLN Lisbon, PORTUGAL; Centro Hospitalar do Porto; Victor Babes Hospital Cohort, Bucharest, ROMANIA; Republican Hospital of Infectious Diseases, St Petersburg, RUSSIA; Irkutsk AIDS Centre, RUSSIA; The City HIV Centre, St Petersburg, RUSSIA; CoRISpe-cat cohort of HIV-infected children, SPAIN; CoRISpe-S cohort of HIV-infected children, SPAIN; Karolinska Institutet; Swiss Mother and Child HIV Cohort Study, SWITZERLAND; Programs for HIV Prevention and Treatment (PHPT), THAILAND; National Surveilliance of HIV in Pregnancy and Childhood and Collaborative HIV Paediatric Study (CHIPS); Collaborative HIV Paediatric Study (CHIPS); Ukraine Paediatric HIV Cohort, UKRAINE
- First posted
- Dec 21, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Across Europe and worldwide, there are many studies following groups (cohorts) of children living with human immunodeficiency virus (HIV) and other infections over time, to monitor their long-term health. Some of these infections are rare: for example, few children in Western Europe are living with HIV, so the studies often have fairly small numbers of participants. This can make it difficult to answer research questions in these cohorts and means that doctors and researchers working with these patients in different countries need to work together. This is particularly important as children are not often included in clinical trials of treatments and other interventions. The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) is an international network of researchers working together in this way. Researchers in the network represent cohort studies of pregnant women and children with, or at risk of, infections from across Europe and Thailand. The research focuses on infections in pregnant women and children, particularly HIV, hepatitis B and C virus, and tuberculosis, and, from 2020, novel coronavirus (COVID-19). By combining data from many cohorts, the researchers aim to answer questions that could not be answered by one study individually (for example, because a large number of pregnant women or children are needed to answer the question). This protocol focuses on the paediatric component of EPPICC's research, which focuses on the treatment of children at risk of and living with infections. For example, what medicines are used most often and how do they affect children's health? EPPICC is an observational study, which means that children do not receive any extra treatment as part of the study. Instead, children are "observed" during their routine medical care. Each cohort keeps records of the children's health collected at routine clinic visits, including information such as date of birth and sex, results of diagnostic tests, treatments received, and any illnesses or other events that the children have had. The EPPICC study combines and analyses data from all of the cohorts that take part, to answer questions about the risks and benefits of different diagnosis or treatment strategies, the long-term effects of infection and treatment during childhood and young adulthood, and regional variations (e.g. between Western and Eastern Europe) in the risk and management of infections. All of the data collected through the EPPICC Paediatric Protocol are stored securely at the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL. Data collection and storage are governed by the General Data Protection Regulation. A Steering Committee guides the research to make sure it is relevant and of high quality. Public and patient involvement (PPI) may be provided by individual cohorts' own groups, as well as by the interlinked Penta organisation, which is a network of paediatricians and researchers working in infections in Europe and globally. The PPI groups help with release of the results of the research. The results are also published on the Penta Foundation's public website (https://penta-id.org/), and presented at conferences and published in Open Access scientific journals.
Conditions
- HIV Infections
- Tuberculosis Infection
- Hepatitis C
- Covid19
Interventions
ART TherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- CD4 count in adulthood of young people with HIV assessed using routine clinical dataTime frame: through study completion, an average of 5 year
- 2. Viral suppression in adulthood of young people with HIV assessed using routine clinical dataTime frame: through study completion, an average of 5 year
- Viral suppression defined as <50 copies, <400 copies and 1000 copies/mL) upto 144 weeks.Time frame: up to 144 weeks
- CD4 change from drug start up to 144 weeksTime frame: up to 144 weeks
- Cumulative incidence of virological failure (>1000 copies/mL)Time frame: through study completion, an average of 5 years
- From start of novel drug of interest through to earliest date of the following: death, loss to follow-up, discontinuation of drug or last visitTime frame: From date of novel drug initiation until earliest date of death, loss to follow-up, discontinuation of drug or last visit assessed up to 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.